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Commentary
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Over the past decades, some scientific progress has been made in understanding and treating cancer-related fatigue (CRF).
However, three major problems have limited further progress: lack of agreement about measurement, inadequate understanding
of the underlying biology, and problems in the conduct of clinical trials for CRF. This commentary reports the recommendations
of a National Cancer Institute Clinical Trials Planning Meeting and an ongoing National Cancer Institute working group to address
these problems so that high-priority research and clinical trials can be conducted to advance the science of CRF and its treatment.
Recommendations to address measurement issues included revising the current case definition to reflect more rigorous criteria,
adopting the Patient Reported Outcomes Measurement Information System fatigue scales as standard measures of CRF, and
linking legacy measures to the scales. With regard to the biology of CRF, the group identified the need for longitudinal research
to examine biobehavioral mechanisms underlying CRF and testing mechanistic hypotheses within the context of intervention
research. To address clinical trial issues, recommendations included using only placebo-controlled trial designs. setting eligibility
to minimize sample heterogeneity or enable subgroup analysis, establishing a CRF severity threshold for participation in clinical
trials, conducting dissemination trials of efficacious interventions (such as exercise), and combining nonpharmacologic and pharmacologic interventions to exploit the potential synergy between these approaches. Accomplishing these goals has the potential
to advance the science of CRF and improve the clinical management of this troubling symptom.
J Natl Cancer Inst;2013;105:1432–1440

Introduction
Over the past decades, we have made progress in our understanding of cancer-related fatigue (CRF) including its definition, measurement in adults and children (1,2), and identification of a few
effective therapies (3–11). Recent research has also explored biomarkers and causal mechanisms of CRF. Despite this progress,
there has been considerable diversity in the conceptual and operational definition of CRF limiting the generalizability of research
findings; incomplete understanding of its biologic basis resulting in
few pharmacologic targets for treatment; and limited clinical dissemination of efficacious behavioral interventions such as exercise.

The Clinical Trials Planning Meeting
The National Cancer Institute convened a Clinical Trials Planning
Meeting (CTPM) on CRF in 2010 to examine the issues and
initiate a process for developing a focused agenda to advance
the science of symptom management in the community setting.
Participants included representatives of academia, community
oncology, government, the pharmaceutical industry, and the patient
community. The overall goal of the CTPM was to set priorities
for clinical trial investigations of CRF and make recommendations
for high-priority research over the next several years. Objectives of
the meeting were to 1) examine what is known about the biologic,
1432
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psychological, and social factors related to fatigue and propose
new studies to uncover the biopsychosocial mechanisms of CRF;
2) synthesize “lessons learned” from randomized clinical trials of
CRF as a basis for setting new directions for clinical intervention
research; 3) review the definition and measurement of CRF
(patient-reported, case definition, and biomarker measures); and
4) explore clinical trial design and analysis issues in CRF research.
These activities were directed to the development of a research
agenda that builds on current knowledge and provides directions
for future research. The CTPM spawned a working group that
has continued the discussion. This commentary incorporates both
the issues and recommendations of the CTPM and the updated
consensus of the ongoing working group.

Background
Fatigue is the most common symptom experienced by adults and
children with cancer (12–18). It can be associated with the cancer
itself, cancer treatment, and/or other symptoms such as depression
or poor sleep. CRF is a complex multidimensional problem characterized by reduced energy and increased need for rest unrelated
to recent sleep or activity that is known to affect quality of life
adversely by reducing mental and physical functioning, disturbing mood, and interfering with usual activities (16,19). CRF is also
Vol. 105, Issue 19 | October 2, 2013

emerging as a dose-limiting toxicity associated with established and
newer therapies including targeted agents (such as tyrosine kinase
inhibitors) that can ultimately limit the effectiveness of treatment
(20). CRF is not always easily differentiated from everyday fatigue
without careful diagnostic evaluation.
The true prevalence of CRF is unknown because differences in
measurement yield a wide range of prevalence estimates depending on the domains of fatigue considered (21). For example, studies that simply ask about self-reported fatigue presence or severity
have yielded prevalence estimates in the range of 70–99% (22).
Studies requiring fatigue to exceed a threshold of severity, duration,
or functional impairment have produced estimates in the 30–70%
range (23). When CRF has been defined as a syndrome with specific diagnostic criteria inclusive of severity, functional impairment,
and duration, prevalence estimates have been considerably lower,
in the range of 15–30% (24,25).
CRF has been documented before the initiation of treatment
(26), during cancer therapy (27–29), in disease-free survivors
(24,30), and at the end of life (13,31,32). Patterns of fatigue during treatment have varied with context. A cyclic pattern of CRF
has been documented with each cycle of chemotherapy followed
by a gradual decline after completion of treatment (33,34). During
radiotherapy, CRF follows a gradually increasing pattern until the
end of treatment with a gradual decline after completion (27,35).
Chronic fatigue has been documented in some disease-free survivors and in most individuals at the end of life (13,24,36). CRF
has been associated with a variety of comorbid problems including
sleep disturbance, psychiatric disturbances such as depression or
anxiety, unrelieved pain, medication side effects, nutritional imbalance, physical inactivity, and certain coping styles (25,27,37–40).
Causal mechanisms of CRF are not well understood. Recent
evidence suggests that inflammatory processes, dysfunction of the
hypothalamic-pituitary-adrenal (HPA) axis, disruption of circadian
rhythms, and disturbance of monoamine pathways that regulate
serotonin, dopamine, and norepinephrine may cause or contribute
to CRF (41–47). However, CRF is known to be rooted in both

biology and behavior, so a simple biological or psychosocial explanation is unlikely; rather, the presence of biopsychosocial causal
mechanisms is more likely. Because of the number and complexity
of factors that could contribute to CRF, a model is provided as an
organizational framework (Figure 1).

Definition and Measurement of
Cancer-Related Fatigue
Conceptual Definition
The NCCN conceptual definition of CRF is widely endorsed and
cited: CRF is “a distressing, persistent, subjective sense of physical,
emotional and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity
and interferes with usual functioning” (21). Furthermore, subjective experience in these domains must interfere with functioning.
The clarity of this conceptual definition and its general acceptance
are congruent with the full case definition of CRF.
Case Definition
A conceptual definition alone lacks the specificity to diagnose a
clinical case of CRF because threshold criteria including type,
number, severity, and chronicity are not clearly articulated. To
identify a case of CRF, one must determine whether a symptom of
tiredness must be present across all three functional (physical, emotional, and cognitive) domains or whether one domain only (eg,
physical) is sufficient (Table 1). Likewise, it is important to decide
how severe the fatigue must be and for what period of time it must
be present. To address these limitations, a set of diagnostic criteria to define CRF was proposed by the Fatigue Coalition (48) and
recognized for inclusion in the International Classification of Diseases
and Related Problems, 10th edition (49,50).
This CRF case definition requires the presence of fatigue and/
or related sensations and a specific number of related symptoms,
evidence of impact on functioning, and inclusion/exclusion criteria
(Table 1) (24,25,31,36,49,50,51–54). However, this case definition

Figure 1. Correlates of cancer-related fatigue. HPA axis = hypothalamic-pituitary-adrenal axis.
jnci.oxfordjournals.org
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Table 1. Proposed International Classification of Disease-10 (ICD-10) criteria for diagnosis of cancer-related fatigue*
A
A1
A2
A3
A4
A5
A6
A7
A8
A9
A10
A11
B
C
D

Six or more of the following symptoms have been present every day or nearly every day during the same 2-week period in the past
month and at least one of the symptoms is (A1) significant fatigue.
Significant fatigue, diminished energy, or increased need to rest, disproportionate to any recent change in activity level
Complaints of generalized weakness or limb heaviness
Diminished concentration or attention
Decreased motivation or interest to engage in usual activities
Insomnia or hypersomnia
Experience of sleep as unrefreshing or nonrestorative
Perceived need to struggle to overcome inactivity
Marked emotional reactivity (e.g., sadness, frustration, or irritability) to feeling fatigued
Difficulty completing daily tasks attributed to feeling fatigued
Perceived problems with short-term memory
Post-exertional malaise lasting several hours
The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning
There is evidence from the history, physical examination, or laboratory findings that the symptoms are a consequence of cancer or
cancer therapy
The symptoms are not primarily a consequence of comorbid psychiatric disorders such as major depression, somatization disorder,
somatoform disorder, or delirium

* Reproduced from Cella et al (48) with permission from the American Society of Clinical Oncology [1998 draft (49)].

could benefit from further revision and validation including specification in the A1 criterion of “significant fatigue” in a specific time
frame such as “most of the day and nearly every day.” The “B”
criterion might benefit from a statement that “fatigue and associated symptoms” are causing distress, as well as specification of
the duration and pervasiveness of the impairment due to fatigue.
Finally, the “D” criterion needs to be clarified to indicate when a
psychiatric disorder is permitted and when it is not. In the context
of a depressive disorder, a concurrent diagnosis of CRF might be
considered only if the fatigue is pervasive and disabling, consistent
with the suggested revisions of A1 and B criteria. Although the current case definition provides a good starting point, further validation of the CRF criteria is recommended to set a rigorous standard
for classifying CRF cases (24,25,36,54, 55).
Self-Report Measures of Cancer-Related Fatigue
As a subjective symptom, CRF is measured most efficiently via
self-report. Numerous reviews of valid and reliable self-report
measures for adults are appropriate for clinical research (1,56–58).
Several reliable and valid instruments are available to evaluate
fatigue in children with cancer including two validated proxy
report instruments (parent and clinician) (2,59–62). Consistent
with the conceptual definition, most self-report scales address both
the sensation and impact domains of CRF (21), and some scales
include additional domains such as reduced motivation, energy or
vitality, or diurnal variation (1). Variability in the outcome domains
assessed by self-report CRF measures has hindered meaningful
comparison across studies and the translation of results into clinical
practice.
Patient Reported Outcomes Measurement Information
System as a Common Metric
Recent developments in the measurement of patient-reported
outcomes have focused on the establishment of so-called item
banks that consist of a large number of patient-reported outcomes
questions/items that have undergone extensive qualitative and

quantitative evaluation to support their validity and reliability. All
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items in the item bank are calibrated on a common metric using
item response theory models to allow comparison of scores from
different item sets within the same item bank. In other words, a
fatigue item bank allows the development of multiple fatigue
short forms that can be targeted to the needs of any clinical trial.
Fatigue scores from the short forms can be compared or combined
across multiple studies (63–66). Recognizing the importance of
patient-reported outcomes item banks, the National Institutes of
Health launched the Patient Reported Outcome Measurement
Information System (PROMIS) initiative to develop a publicly
available set of standardized self-report measures of symptoms and
other health domains including both pediatric and adult measures
of fatigue (64). The adult PROMIS item bank includes 95 items,
54 of which were retained in a cancer-specific application, measuring an individual’s fatigue experience and the impact of fatigue on
daily living. The pediatric PROMIS item bank includes 23 items
measuring key domains of energy and capacity for physical functioning, psychosocial effects, and anemia-specific concerns. The
pediatric PROMIS fatigue measure also differentiates between 8to 18-year-olds who are on treatment or in survivorship (67,68).
The adult PROMIS fatigue measure has been validated with
fatigue measures commonly used in research (referred to as
“legacy” scales) including the 13-item Functional Assessment of
Chronic Illness Therapy-Fatigue and the 4-item SF-36 Vitality
Scale (69,70). The PROMIS fatigue measure was found to be highly
correlated with the legacy measures, and PROMIS scores statistically significantly differentiated cancer survivors at different points
of the care continuum and different stages of disease. In addition,
the PROMIS measure differentiated individuals with different
levels of performance status using the rating scale developed by the
Eastern Cooperative Oncology Group (71,72). Demographic correlates of PROMIS fatigue in the US general population included
sex (women more than men), marital status (married more than
unmarried), and age (younger more than older) (65). Race/ethnicity
was also collected, and the PROMIS fatigue measure did not show
differential item function by race (non-Hispanic whites, African
Americans, Hispanics), but more analyses need to be conducted.
Vol. 105, Issue 19 | October 2, 2013

Future studies are planned to estimate minimally important differences (MIDs) for the pediatric and adult PROMIS measures.
An MID is defined as the minimal change in fatigue level that is
perceived by patients or clinicians as meaningful. Different from
statistical significance, the MID can serve as a clinically meaningful
indicator of the safety or efficacy of an intervention (73). The MID
has been addressed in advanced cancer with varied results depending on the approach used to estimate the MID (73).
A potential benefit of PROMIS is that it offers an opportunity
to link legacy CRF measures such as the Functional Assessment
of Chronic Illness Therapy-Fatigue to the PROMIS fatigue
measure and vice versa. This would enable comparisons across
research results (74). Linking other legacy measures with PROMIS
is encouraged. This reconciliation process could be especially
beneficial in pediatrics that relies on age-specific measures. Children
as young as 7 years of age can describe CRF in simple terms such
as activity and lifestyle limitations; older school-age children can
describe it in greater detail (75,76). Adolescents describe CRF with
more abstract detail highlighting mental tiredness and physical
fatigue (59,67). As a child moves from one age group to another,
different forms of developmentally appropriate CRF measures
that have been reconciled could be used to allow for longitudinal
comparisons across different time points. Efforts are underway to
validate common items between pediatric and adult CRF with a
goal of developing a life span fatigue item bank.

Recommendations
•• Update and revise the current case definition of CRF to reflect a
more rigorous and specific description of the criteria.
•• Adopt the PROMIS Fatigue item banks and their short forms
(pediatric and adult) as standard measures of CRF severity and
impact.
•• Identify and take opportunities to link legacy CRF measures
with PROMIS fatigue measures.
•• Examine the validity of the PROMIS-Fatigue item bank in
predicting behavioral outcomes such as work performance for
adults and school performance for children.
•• Examine differences in CRF levels by race/ethnicity.
•• Evaluate minimally important differences in CRF for different
clinical groups.

The Biology of CRF
To date, CRF has been understood largely as a subjective patientreported experience, limiting our knowledge of its pathophysiology. Research has shown that biologic mechanisms are involved in
a broad range of psychosocial and behavioral sequelae including
CRF. However, the precise physiologic pathways involved in the
development of CRF and its relationship to the cancer experience
are poorly understood. Inflammatory processes, HPA-axis function, and circadian rhythms are interrelated regulatory networks
that communicate with each other through multiple signaling pathways, and all have been proposed as mechanisms underlying CRF
(77–79). Understanding the biologic processes underlying CRF
is critical to the identification of potential targets for therapeutic
intervention. There is evidence of biologic dysregulation across
jnci.oxfordjournals.org

cancer diagnoses and treatment modalities (80,81). However, due
to a lack of systematic study of these potential confounding variables, it is not known if the mechanisms of symptom development
and persistence differ by tumor and/or treatment type, although
recent findings do not show substantial effects of treatment type in
breast cancer survivors (47).
By far the most studied mechanism is the inflammatory process.
Animal studies have shown that tissue damage or infection results in
the release of proinflammatory cytokines that can signal the central
nervous system, leading to a constellation of behavior changes
known as “sickness behavior” (82–84). In humans, cytokines are
released in response to cancer and/or its treatment resulting in selfreported symptoms similar to animal sickness behaviors, of which
fatigue is prominent. Findings from numerous studies over the past
decade support an association between cytokine activity and fatigue,
although results have been mixed (85–87). Research focused on
pathways by which cytokines interact with neurocircuits in the
brain have also been explored (88). Several studies have shown that
inflammatory cytokines as well as inflammatory stimuli lead to
changes in neural activity in the basal ganglia that in turn have been
associated with symptoms of fatigue (89).
Upregulated cytokine signaling has been associated with other
processes including HPA-axis dysfunction (89,90). In the normal physiologic environment, cortisol is released from the adrenal glands in a circadian pattern. One of its functions is to inhibit
proinflammatory cytokine production and activity during acute
stressful events (91). During chronic exposure to proinflammatory
cytokines (as may occur in cancer and cancer therapies), the sensitivity of the HPA axis is thought to be blunted; this decrease in
cortisol production has been associated with CRF (91,92).
Circadian rhythms are the regular daily cycles of activity and
rest controlled by the suprachiasmatic nucleus in the brain. Robust
synchronized circadian rhythms are important to health and wellbeing (78,93). HPA axis dysfunction and inflammation have been
associated with disruption of circadian rhythms (94) and result
in symptoms such as fatigue, sleep disturbance, and depression.
Disrupted circadian rhythms have also been associated with mortality in older men and women, dementia, and cancer (95–99).
Emerging evidence suggests that individuals with CRF have dysregulated circadian activity/rest and sleep/wake rhythms including
less daytime activity, later sleep onset at night, and more frequent
awakening (53,93,100,101). CRF that worsens during chemotherapy has also been associated with progressively worse and more
enduring impairment of circadian activity rhythm (46).
Recent investigations have focused on genetic influences on
symptoms including CRF. Technological advances and completion
of the mapping of the human genome have enabled the development of new tools for scanning the entire genome or examining
candidate genes that could control the development and persistence
of CRF. Several investigations have identified gene polymorphisms
or variants that characterize individual differences in the severity of
CRF (44). Most of this work on the genetics of CRF has focused
primarily on genes involved in inflammatory pathways (102,103).
Other research has focused on gene expression as an explanation of
underlying mechanisms because expression involves not only the
heritable aspects (gene variants) but also alterations due to environmental changes (41,104,105). The study of gene polymorphisms
JNCI
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and gene expression has the potential to yield important information about the mechanisms that control CRF including onset,
persistence, and resolution (106). However, it would require large
study samples.

Recommendations
•• Conduct longitudinal research to examine the interrelated
biobehavioral mechanisms underlying CRF.
•• Test mechanistic hypotheses within the context of CRF intervention research.
•• Test new hypotheses about CRF mechanisms in animal models
that control for the specific effects of tumor and treatment.

Interventions for Cancer-Related Fatigue
Nonpharmacologic Interventions
The research literature on nonpharmacologic intervention for
CRF is substantial encompassing several broad categories of psychosocial therapies and physical activity. Three meta-analyses
showed that psychosocial interventions had a small to moderate
effect on CRF (5,7,8). However, psychosocial therapies comprise a
diverse set of educational, supportive, and behavioral interventions,
so conclusions cannot be drawn about the benefit of specific components (8,107). To date, numerous meta-analyses have shown that
exercise intervention had a statistically significant effect on CRF
with magnitudes in the small to moderate range (3–5,8,9,11,108–
110). Exercise with aerobic and strength training components (150
minutes per week of moderate to strenuous intensity activity and
two to three weekly sessions focused on major muscle groups,
respectively) was found to be more effective in reducing CRF than
aerobic exercise alone (4), and supervised exercise was found to be
more effective than home-based exercise (4). Recent studies have
also demonstrated the benefit of physical activity for individuals
with advanced cancer (111,112). Most research on the mechanisms
underlying the benefit of exercise for cancer patients and survivors
is derived from research in healthy populations (113,114). A few
studies have examined inflammatory changes or insulin resistance
related to exercise in cancer survivors but not in connection with
CRF (115–119).
The wealth of positive meta-analysis results for psychosocial
and exercise interventions suggest the need for further research
aimed to increase the effect size of beneficial interventions as well
as dissemination studies to evaluate beneficial interventions such
as exercise in community settings. Future studies should address
motivational factors and barriers to implementation of exercise
and psychosocial interventions as well as adherence (120,121).
The patient advocates who participated in the CTPM recommended the conduct of exercise intervention trials for survivors
that are practical and exportable, addressing safety issues, appropriate regimens for different climates, and motivation as a key factor related to uptake of the intervention. Based on the evidence,
the American College of Sports Medicine has published extensive
exercise guidelines for different types of cancer that have implications for CRF (122).
There are many remaining questions about nonpharmacologic
interventions that would be worthy of pursuit including yoga
1436
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(123–125), mindfulness-based stress reduction (126,127), cognitive
behavioral therapy for insomnia (128–133), and light treatment for
prevention of CRF (134). In the current climate of personalized
medicine, there may be a place for trials of tailored interventions
powered for subgroup analysis with regard to efficacy for different
groups based on demographic, medical, nutritional, and functional
status. The ability to conduct large nonpharmacologic intervention
trials would require additional resources. Nonpharmacologic
interventions are generally labor intensive, and the intervention
often requires delivery by staff with specialized training.
Investigators may also consider more efficient use of resources by
conducting telephone- and/or Internet-based intervention studies.
Pharmacologic Interventions for Cancer-Related Fatigue
In contrast to the sizable amount of research on nonpharmacologic interventions for CRF, the pool of studies of pharmacologic
interventions is much smaller and based largely on benefit in
other diseases (such as multiple sclerosis) or conditions (such as
advanced cancer). There has been only one systematic review and
meta-analysis of 27 randomized controlled trials of pharmacologic
treatment for CRF (135). The analysis was done by drug type, and
the overall effect size for all drug classes was small. Based on two
studies, methylphenidate, a sympathomimetic psychostimulant, was
shown to be more effective than placebo. The antidepressant paroxetine was evaluated in two trials, but no CRF benefit was observed.
Three studies examined progestational steroids, but no CRF benefit
was found. Although 10 studies of erythropoietin in anemic cancer patients undergoing chemotherapy found that it was superior
to placebo and four trials of darbepoetin demonstrated superiority,
current concerns about cardiovascular safety and reduced disease
control suggest that these drugs should be used with caution for the
management of CRF associated with anemia (136,137).
Another wakefulness-promoting agent, modafinil, was evaluated
in one randomized controlled trial (138). The trial was negative
overall; in secondary analysis, modafinil was found to be effective
for individuals presenting with severe fatigue, suggesting the need
for further evaluation of this drug. Another drug with potential
for CRF management is bupropion, a norepinephrine dopamine
reuptake inhibitor, with favorable results in two open-label trials
(139). Nonsteroidal antiinflammatory drugs and other drugs with
direct and indirect cytokine antagonistic effects should also be
considered for future intervention trials.
Overall, advancement of the science of CRF management
requires new approaches to the study of both nonpharmacologic
and pharmacologic interventions. First, most previous research has
lacked a theoretical framework and hypothesis testing about the
potential biopsychosocial mechanisms underlying CRF. Moving forward, it is imperative that intervention efficacy research be coupled
with examination of hypotheses about the mechanisms by which
interventions achieve their effects. Second, the strength of evidence
in favor of physical activity intervention (including aerobic and
strength-building components) suggests that dissemination research
is in order. Future studies need to focus on overcoming barriers to
implementation in the community setting and strategies to increase
uptake and effect size of physical activity interventions. Third, given
the strong likelihood of the placebo effect related to interventions
for CRF, placebo-controlled studies are critical to the demonstration
Vol. 105, Issue 19 | October 2, 2013

of efficacy and remain the gold standard (140). Fourth, there is great
potential for synergy between nonpharmacologic and pharmacologic
interventions that should be exploited to enhance the effect size of
interventions. Fifth, CRF is a heterogeneous condition that is likely
to be affected by demographic, medical, nutritional, and functional
status. Careful consideration needs to be given to eligibility for participation in clinical trials of CRF management to minimize heterogeneity. Moreover, consideration needs to be given to the severity of
CRF as an eligibility criterion because at least one study found that
efficacy of a drug intervention was limited to individuals with severe
fatigue (138), and most previous intervention trials did not have a specific inclusion criterion limiting eligibility to fatigued individuals (8).

5.

6.

7.

8.

9.

Recommendations
•• Conduct research with randomized placebo-controlled trial
designs, and consider the use of recently developed strategies
such as the doubly randomized preference trials.
•• Carefully consider eligibility for CRF intervention trials to minimize sample heterogeneity or enable subgroup analysis.
•• Establish a threshold of symptom severity for participation in
CRF clinical trials.
•• Conduct dissemination trials of efficacious interventions (such
as exercise) focused on overcoming barriers to implementation
and strategies to increase uptake and effect size of interventions.
•• Combine nonpharmacologic and pharmacologic interventions
to exploit the potential synergy between these two approaches.

Summary
Although much has been accomplished over the past decades, there
is a need to focus future research in critical directions to advance
the science of CRF management. This commentary reports the
recommendations of participants in a National Cancer Institute
CTPM and an ongoing National Cancer Institute working group
for high-priority clinical trial investigations of CRF over the next
several years. Three areas of science have been addressed in this
commentary: measurement, biology, and intervention for CRF.
Implementation of these recommendations has the potential to
1) advance our understanding of the biobehavioral mechanisms
of CRF; 2) identify new targets for intervention to prevent or
treat CRF; 3) accomplish the dissemination of efficacious interventions into the community; and 4) leverage the yield beyond
individual studies by pooling and comparing data across studies.
Accomplishing these goals will advance the science of CRF and
improve the clinical management of this troubling symptom.
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